Donna Rocha, MD
Psychiatry · Springdale, ARNPI 1780666495
Payments from drug & device makers
Across 88 payments — averaging $14.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$241
- AbbVie$187
- Alkermes, Inc.$173
- Neurocrine Biosciences, Inc.$142
- Lundbeck LLC$110
- Johnson & Johnson$106
- plus $302 from 6 others
What the payments were for
- Food & beverage$1,24899%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $241 |
| AbbVie(2 entities) | 24 | $187 |
| Alkermes, Inc. | 8 | $173 |
| Neurocrine Biosciences, Inc. | 10 | $142 |
| Lundbeck LLC | 6 | $110 |
| Johnson & Johnson | 7 | $106 |
| E.r. Squibb & Sons, L.L.C. | 1 | $80 |
| Vanda Pharmaceuticals Inc. | 5 | $76 |
| Ironshore Pharmaceuticals Inc. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$1,261 in reported general payments places this provider in the 65th percentile of 235 psychiatry providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 42 | $351,452 |
| AustedoDeutetrabenazine | 26 | $197,497 |
| Invega SustennaPaliperidone Palmitate | 54 | $170,021 |
| VraylarCariprazine Hcl | 100 | $148,702 |
| AristadaAripiprazole Lauroxil | 24 | $80,004 |
| Abilify MaintenaAripiprazole | 22 | $57,400 |
| Lurasidone Hcl | 110 | $39,598 |
| Risperdal ConstaRisperidone Microspheres | 23 | $29,226 |
| TrintellixVortioxetine Hydrobromide | 47 | $25,892 |
| Aripiprazole | 248 | $23,497 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $18,990 |
| VyvanseLisdexamfetamine Dimesylate | 34 | $12,906 |
| Clozapine | 146 | $11,409 |
| BelsomraSuvorexant | 18 | $8,170 |
| Chlorpromazine Hcl | 36 | $7,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $142 | $351,45242 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $106 | $199,24777 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $11 | $197,49726 claims |
| AbbVieVraylar | $187 | $148,702100 claims |
| Alkermes, Inc.Aristada, Lybalvi | $173 | $98,99436 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $241 | $57,40022 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $48 | $38,79781 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 235 psychiatry providers in Arkansas.
Other psychiatry in Springdale
- Lance FosterSpringdale$4K
- Leslie SmithLittle Rock$7.9M
- Gintaras AukstuolisLittle Rock$6.6M
- Robert BillingsleyFayetteville$5.9M
- Paul WylieLittle Rock$3.4M
- Robert WootenPine Bluff$945K
- Prasad PadalaNorth Little Rock$868K
- Tad TillemansLittle Rock$656K
- Steven KoryElm Springs$628K
- Renea HendersonLittle Rock$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.